Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

Glucagon and glucagon-like peptide (GLP)-1 are the primary products of proglucagon processing from the pancreas and gut, respectively.

The researchers aimed to observe the effect of a combination of glucagon and GLP-1 on resting EE and glycemia in healthy human volunteers.

Who Took Part

According to the abstract, 10 volunteers were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Glucagon and who got the comparison, which limits bias.

Blinding on both sides kept the volunteers and researchers unaware of who received Glucagon.

Some volunteers received a placebo instead of Glucagon, giving a reference point.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

What Was Measured

Glucagon and glucagon-like peptide (GLP)-1 are the primary products of proglucagon processing from the pancreas and gut, respectively.

The subject headings attached to it are Calorimetry, Indirect, Energy Metabolism, Glucagon, Glucagon-Like Peptide 1 and Hyperglycemia.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 10 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2013 (Diabetes), a journal based in United States.

More context: the Glucagon compound page, all human trials.